Breaking News
Get 45% Off 0
💰 With a 129% YTD gain in the bag, these are our AI’s top global picks for March
Read now

Chart Of The Day: Moderna Outlook Improves After J&J Vaccine Pause

By Investing.com (Pinchas Cohen)Stock MarketsApr 14, 2021 23:04
au.investing.com/analysis/chart-of-the-day-moderna-outlook-improves-after-jj-vaccine-pause-200459832
Chart Of The Day: Moderna Outlook Improves After J&J Vaccine Pause
By Investing.com (Pinchas Cohen)   |  Apr 14, 2021 23:04
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
PFE
+1.87%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
+0.52%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
+0.04%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
+3.82%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Yesterday, the US Food and Drug Administration halted the use of Johnson & Johnson's (NYSE:JNJ) one-shot coronavirus vaccine when a rare blood-clotting disorder developed in six women between the ages of 18-48 and one died. After the announcement, Moderna (NASDAQ:MRNA) quickly, and appropriately, defended its own vaccine, which the company pointed out, uses a different technology.

While the FDA was careful in its language, calling the stop a “pause,” it could create a serious setback for the Biden administration's ongoing efforts to ramp-up vaccination efforts across the country as inoculation supplies will likely diminish, at least in the short run. In addition, this setback could convince people already uneasy about the vaccines to decide not to vaccinate at all.

After the J&J news broke, some of that changed. Markets beat up on JNJ and AstraZeneca (NASDAQ:AZN), whose vaccine is also causing worrying side effects in a small number of recipients. Shares of both pharmaceutical companies dropped yesterday on Wall Street.

Ironically, we wrote about Pfizer (NYSE:PFE) on Tuesday for this column, before the JNJ pause was announced. In our view at the time, Pfizer's fundamental and Moderna's technical outlook were the strongest among its vaccine competitors.

Conversely, Moderna surged, outperforming all competitors, to gain 7.4%. The upside looks like it might just be getting started too.

MRNA Daily
MRNA Daily

Chart powered by TradingView

After the stock slipped for a few days in late March, to fall below a rising channel, the price rebounded strongly into it. There it found clear support at the bottom of the pattern.

The price’s decline was structured within a falling channel, but that soon morphed into a falling wedge, bullish after the 86% catapult that occured in less than 15 weeks which preceded the wedge. This is considered a continuation pattern, as it shows how, despite the overselling—which is understandable after an incredibly profitable run, illustrated by a faster falling trend line—buying was able to support the price, represented by a slower falling trend line. This indicates that once supply runs out, demand will carry prices higher.

A falling wedge’s target is its top, which agrees with the expectation that a price that bounces off the bottom of a rising channel will retest the previous high on its way to the channel top.

Trading Strategies – Long Position Setup

Conservative traders should wait for a return-move to ascertain there's sufficient demand to push prices back upwards.

Moderate traders would wait for the same pullback for a better entry, if not for the additional confirmation.

Aggressive traders could enter at will, having understood the increased risk of lesser evidence of the uptrend as the price to pay for increased reward for moving ahead of the rest of the market.

A trade plan is essential; here’s an example of a basic one:

Trade Sample

  • Entry: $150
  • Stop-Loss: $130
  • Risk: $20
  • Target: $210
  • Reward: $60
  • Risk:Reward Ratio: 1:3

Author's Note: This is just a sample. There are a variety of approaches to this trade. We’ve selected a price that never existed for a target to justify the risk. A trader could wait for a dip, to limit exposure from the presumed pattern’s demand or place his stop closer but without as much support. The risk in the former is missing out on the trade if there’s no corrective decline; the hazard in the latter is that it will be stopped out for a lack of support.

You must develop the style that suits your timing, budget and temperament. Until then, take small risks for the purpose of learning and gaining experience. Don’t delude yourself that you can make quick profits immediately. If you do, you won't learn anything but you could lose your shirt.

Chart Of The Day: Moderna Outlook Improves After J&J Vaccine Pause
 

Related Articles

Dr. Arnout ter Schure
Is the Nasdaq 100 in a Long-Term Bear Market? By Dr. Arnout ter Schure - Mar 07, 2025

Using the Elliott Wave Principle (EWP), we have been tracking the most likely path forward for the Nasdaq 100 (NDX). Although there are many ways to navigate the markets and to...

Chart Of The Day: Moderna Outlook Improves After J&J Vaccine Pause

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email